Dermatology

Mesoblast develops portfolio of mesenchymal cells to target multiple medical needs

Corium posts top-line interim results of transdermal Alzheimer’s patch for once- weekly dosing

Phase 2 data is positive for Foamix’s acneiform rash treatment

The organizations will advance the clinical development of VAL-083 in glioblastoma multiforme

Astellas will transfer its global dermatology business to LEO Pharma for €675 million

Saliva and plasma testing finds head and neck tumor DNA

AstraZeneca will receive $100M up front, with the potential for pre-launch milestones of up to $170M and sales milestones of up to $175M

Scioderm 's lead drug candidate Zorblisa in Phase 3 study for rare disease epidermolysis bullosa (EB) granted FDA Breakthrough Therapy Designation

Phase 2b results show that blockade of IL-23 resulted in significant skin clearance, with improvements through week 40

Allergan looks to bolster existing facial aesthetics business with acquisition

Amarantus BioScience, U.S. Army and Rutgers University to expand development of engineered skin substitute for treatment of severe burns

Additional positive proof-of-concept data from in-vivo pre-clinical studies of new treatment for recessive dystrophic epidermolysis bullosa highlighted